Anti-VEGF medications containing humanized antibody that blocks angiogenesis by inhibiting VEGF-A have already entered the market to treat a number of cancers, such as colon cancer, lung cancer, glioblastoma and renal cell carcinoma, as well as age-related macular degeneration [15–17]. This evidence concerns the gene VEGFA and hereditary clear cell renal cell carcinoma.